Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.63 |
| ▸ | PTGES | O14684 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7695802 | 0.86 | MAPK14 (0.53) | MAPK14PTGESALOX5TSHRGAA | |
| SCHEMBL3060251 | 0.84 | TSHR (0.71) | MAPK14PTGESALOX5TSHRGAA | |
| SCHEMBL3064954 | 0.82 | MAPK14 (0.49) | MAPK14TSHRGAARAB9APDK1 | |
| SCHEMBL3052776 | 0.81 | TSHR (0.59) | MAPK14PTGESALOX5TSHRGAA | |
| SCHEMBL3060156 | 0.81 | MAPK14 (0.66) | MAPK14PTGESALOX5TSHRGAA | |
| SCHEMBL3057341 | 0.81 | TSHR (0.59) | MAPK14PTGESALOX5TSHRGAA | |
| SCHEMBL3061617 | 0.80 | MAPK14 (0.50) | MAPK14TSHRGAANPC1RAB9A | |
| SCHEMBL3054466 | 0.80 | NPC1 (0.66) | MAPK14PTGESALOX5TSHRGAA | |
| SCHEMBL3065531 | 0.80 | TSHR (0.54) | MAPK14TSHRGAANPC1RAB9A | |
| SCHEMBL2162478 | 0.80 | ROCK1 (0.53) | MAPK14TSHRGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| WO-2002042276-A1 | QUARTERNARY PROFORMS OF TERTIARY AMINE CONTAINING COMPOUNDS | LEO PHARMA A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | MAPK14 3886/4885PTGES 1788/4885ALOX5 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.